%0 Journal Article
%A Koerber, Stefan A
%A Will, Leon
%A Kratochwil, Clemens
%A Haefner, Matthias F
%A Rathke, Henrik
%A Kremer, Christophe
%A Merkle, Jonas
%A Herfarth, Klaus
%A Kopka, Klaus
%A Choyke, Peter L
%A Holland-Letz, Tim
%A Haberkorn, Uwe
%A Debus, Juergen
%A Giesel, Frederik
%T 68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.
%J Journal of nuclear medicine
%V 60
%N 2
%@ 2159-662X
%C New York, NY
%I Soc.
%M DKFZ-2018-01906
%P 234-240
%D 2019
%Z vol. 60 no. 2 234-240
%X The present study analyzed the impact of Gallium-68 (68Ga)-labeled prostate-specific membrane antigen-HBED-CC (68Ga-PSMA-11) positron-emission tomography (PET)/computed tomography (CT) on radiotherapeutic management in a large cohort of men with primary or recurrent disease. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68Ga-PSMA-11 PET/CT as well as conventional imaging. 50 patients were treatment naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery and 60 presented with recurrent PSA following definitive therapy. Changes in TNM classification of malignant tumors (TNM) stage and radiotherapeutic management after 68Ga-PSMA-11 imaging were compared to results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29976697
%R 10.2967/jnumed.118.211086
%U https://inrepo02.dkfz.de/record/141400